Fusion Antibodies (LON:FAB) Trading Up 14.1% – What’s Next?

Fusion Antibodies plc (LON:FAB) shares traded up 14.1% on Tuesday . The company traded as high as GBX 11 and last traded at GBX 10.55. Approximately 1,644,497 shares were traded during trading, an increase of 288% from the average session volume of 424,310 shares. The stock had previously closed at GBX 9.25.

Fusion Antibodies Price Performance

The company has a debt-to-equity ratio of 92.42, a current ratio of 1.80 and a quick ratio of 2.36. The stock has a market capitalization of £13.20 million, a price-to-earnings ratio of -7.03 and a beta of 1.24. The stock’s 50 day simple moving average is GBX 10.84 and its 200-day simple moving average is GBX 12.16.

Fusion Antibodies (LON:FAB) last issued its quarterly earnings data on Monday, September 14th. The company reported GBX (1.20) EPS for the quarter. Fusion Antibodies had a negative net margin of 91.92% and a negative return on equity of 210.32%. On average, analysts expect that Fusion Antibodies plc will post -129.9999875 EPS for the current fiscal year.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.